Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11991611 | 0.94 | SCN9A (0.32) | SCN9AMRGPRX4GAAMCOLN3NPSR1 | |
| SCHEMBL11922613 | 0.92 | SCN9A (0.35) | SCN9AMRGPRX4GAAMCOLN3NPSR1 | |
| SCHEMBL11991608 | 0.91 | SCN9A (0.33) | SCN9AMRGPRX4GAAMCOLN3NPSR1 | |
| SCHEMBL11991613 | 0.90 | MRGPRX4 (0.33) | SCN9AMRGPRX4GAAMCOLN3NPSR1 | |
| SCHEMBL11991615 | 0.90 | MRGPRX4 (0.33) | SCN9AMRGPRX4GAAMCOLN3NPSR1 | |
| SCHEMBL11991503 | 0.87 | LTC4S (0.32) | SCN9AGAAMCOLN3NPSR1MEN1 | |
| SCHEMBL11991502 | 0.85 | SCN9A (0.30) | SCN9AMRGPRX4 | |
| SCHEMBL11922556 | 0.83 | MRGPRX4 (0.35) | SCN9AMRGPRX4GAAMCOLN3NPSR1 | |
| SCHEMBL11922612 | 0.81 | SCN9A (0.35) | SCN9AMRGPRX4GAAMCOLN3NPSR1 | |
| SCHEMBL11922611 | 0.81 | SCN9A (0.35) | SCN9AMRGPRX4GAAMCOLN3NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912182-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912182-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8541402-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541402-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8476257-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-02 | — | — | US | disclosed |
| US-8476257-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-02 | — | — | US | disclosed |
| US-20120214783-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214783-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20110021486-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021486-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| WO-2009076747-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021486-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2B, POLR2H | SCN9A 2294/4885MRGPRX4 2825/4885GAA 1929/4885 |
| US-20120214783-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2B, POLR2H | SCN9A 2294/4885MRGPRX4 2825/4885GAA 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.